Related Experiment Video
Updated: Aug 17, 2026

The 6-hydroxydopamine Rat Model of Parkinson's Disease
Published on: October 27, 2021
L-dopa and apomorphine disrupt long- but not short-behavioural chains
Abstract:
Apomorphine (0.01-0.5 mg/kg) disrupted fighting between two male ferrets. The number of bites and neck nuzzling were decreased dose-dependently. At 0.05 and 0.1 mg/kg scent-marking and collateral behaviour were increased, at 0.5 mg/kg stereotyped sniffing was induced. L-dopa (120 mg/kg + 30 mg/kg benserazide) exerted similar effects to apomorphine 0.05 mg/kg. Thus, the dopamine (DA) agonists increased short chain responses but disrupted long ones. Haloperidol (0.2 mg/kg) facilitated inter-male fighting. The number of bites increased, but scent-marking and collateral behaviour were selectively suppressed. Thus, the persistency of the long behavioural chain was enhanced. Since, at lower doses, DA-agonists expand and DA-antagonists selectively narrow the range of exhibited behavioural responses, it is suggested that the degree of stimulation of central DA-receptors determines the animal's ability to suppress responses that compete with ongoing behaviour.
Related Concept Videos
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Drugs Affecting Neurotransmitter Synthesis
Drug Abuse and Addiction: Pharmacological Phenomena
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

